Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Infect Dis Rep. 2006 Mar;8(2):91-5.

Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond.

Author information

  • Division of Infectious Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Case Medical Center, 1110 Euclid Avenue, Cleveland, OH 44106, USA. david.bobak@case.edu

Abstract

The United States Food and Drug Administration has approved the parasiticidal agent nitazoxanide for treatment of diarrhea caused by Giardia lamblia/intestinalis or Cryptosporidium parvum. This novel agent has a broad spectrum of activity against many other gastrointestinal pathogens, including bacteria, roundworms, flatworms, and flukes. Nitazoxanide is used in many areas of the world, especially in Central and South America, as a broad-spectrum parasiticidal agent in adults and children. Nitazoxanide appears to be well tolerated, has a relatively low incidence of adverse effect, and displays no significant known drug-to-drug interactions. Recently, preliminary reports indicate that nitazoxanide may be an effective treatment for Clostridium difficile-associated diarrhea as well. Future work will likely solidify and further expand the role of nitazoxanide in the treatment of a wide range of intestinal pathogens.

PMID:
16524544
[PubMed]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk